AZD-7624
- Generic Name
- AZD-7624
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma
Phase 2
Completed
- Conditions
- Corticosteroid Resistant (CR) Asthmatics
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 2
- Registration Number
- NCT02753764
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01937338
- Locations
- 🇬🇧
Research Site, London, United Kingdom
To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01817855
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo to match
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT01754844
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath